Safety and immunogenicity of a varicella vaccine without human serum albumin (HSA) versus a HSA-containing formulation administered in the second year of life: a phase III, double-blind, randomized study

Autor: Klaus Helm, Miguel Angel Rodriguez Weber, Ulrich Behre, Jolanta Bernatoniene, Carmen Baccarini, Carlos Eduardo Medina Pech, Paul Gillard, Katrina Cathie, Matthew D. Snape, Maguelone Le Roy, Saul N. Faust, Ouzama Henry, Chitsanu Pancharoen, Michael Povey

Publikováno v: Faust, S N, Le Roy, M, Pancharoen, C, Weber, M A R, Cathie, K, Behre, U, Bernatoniene, J, Snape, M D, Helm, K, Medina Pech, C E, Henry, O, Baccarini, C, Povey, M & Gillard, P 2019, ' Safety and immunogenicity of a varicella vaccine without human serum albumin (HSA) versus a HSA-containing formulation administered in the second year of life : A phase III, double-blind, randomized study ', BMC Pediatrics, vol. 19, no. 1, 50 . https://doi.org/10.1186/s12887-019-1425-7
BMC Pediatrics
BMC Pediatrics, Vol 19, Iss 1, Pp 1-8 (2019)

BACKGROUND: A new formulation of the live-attenuated varicella vaccine Varilrix (GSK) produced without human serum albumin (HSA) was developed to minimize a theoretical risk of transmission of infectious diseases. A previous study showed that the vac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26ea0e09aafc69a2dbac64344c4a5bb7
https://eprints.soton.ac.uk/428490/